Brain Cancer Treatment Market is Segmented By Therapy (Immunotherapy, Immunotherapy. Targeted Therapy, Others), By Stages(Stage I, Stage II, Stage |||, Stage IV), By Indication(Pituitary Tumor, Meningioma, Glioblastoma, Others), By Type(Primary brain cancer(benign), Secondary brain cancer(malignant)), By End-User(Hospitals, Cancer Centers, Diagnostic Centers, Ambulatory Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Brain Cancer Treatment Market is expected to reach at a CAGR of 10% during the forecast period (2024-2031).
Brain Cancer Treatment Market
|
Metrics |
Details |
|
Market CAGR |
10% |
|
Segments Covered |
By Therapy, By Stages, By Indication, By Type, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Brain cancer is caused by the overgrowth of cells in the brain, which results in masses known as tumors. There are two types of brain cancer primary brain cancer and secondary brain cancer. Primary brain cancer develops in the brain tissue, whereas secondary brain cancer develops elsewhere in the body and spreads to the brain tissue. Symptoms include balance problems, seizures, sleep difficulties, unusual behavior.
Brain Cancer Treatment Market Dynamics
Brain cancer treatment market growth is driven by the increasing instances of brain cancer cases across the globe, increase in awareness of treatment option for brain cancer cases, favorable reimbursement polices and increase in government funding in healthcare sectors.
The increase in prevalance of brain cancer cases in the market will drive the market growth
The prevalence of brain cancer such as pituitary tumor and meningioma is driving the global brain cancer treatment market market. Brain cancer is a mix of psychiatric, developmental, and neurodegenerative diseases and it is becoming a common cause of morbidity around the world.. According to the American Medical Association (AMA), more than 20% of the global population would be over 65 years old by 2050. Furthermore, by 2030, at least 60% of those aged 65 and up would have more than one chronic illness. As a result, the growing prevalence of these neurological illnesses around the world is driving the expansion of the brain cancer treatment market.
Furthermore, the prevalence of brain cancer is increasing at a steady rate in developed countries. This contributes to the growth of the global brain cancer treatment market market.
High cost of diagnosis is likely to hamper the market growth
High cost of treatment is the major drawback which is likely to hamper the market. Majority of under developed and developing countries are facing this problem due to less share from the government sector. The high cost of anti-cancer drugs is a major issue for citizens in many countries. There is a lot of pressure to cut costs and show value. NextSource Biotechnology's drug treats glioblastoma and other brain tumors and can cost up to $1000 per capsule.
COVID-19 Impact Analysis
The global market for brain tumour treatments has benefited from the COVID-19 outbreak. With regard to the COVID-19 situation, several segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&D skills, and increased their manufacturing management and quality control investments.
According to 2020 Roche's quarterly reports, the company's global supply network for medicine and diagnostic tests remains intact, and pharmaceutical division sales increased by 7% over the previous year. The efficacy of oncology medications like ecentriq and Perjeta was credited with this rise. Other major players have noticed a similar trend in brain tumour medication sales. They saw an increase in global demand for oncology medications. During the global COVID-19 pandemic, market companies have responded to the rising demand for oncology medications.
Brain Cancer Treatment Market Segment Analysis
The immunotherapy segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Immunotherapy is expected to grow at the fastest CAGR druing the forecast period. It is used to treat cancer either by activating or suppressing the immune system. Immunotherapy is mostly preferred in the treatment of glioblastoma multiforme, which is the most common primary malignant brain cancer in adults.
AstraZeneca developed AstraZeneca AZD1390 which is a highly potent brain penetrant ATM(Ataxia telangiectasia mutant) kinase inhibitor that block ATM-dependent signalling and repair of DNA double –strand breaks (DSBs) in the region.
Increasing R&D initiatives to develop the immunotherapeutics to treat the brain tumors and continuous support from the government authorities to develop the chance therapeutics are projected to fuel the segment growth over the forecast period
Brain Cancer Treatment Market Geographical Analysis
North America region holds the largest market share of global brain cancer treatment market
North America is expected to dominate the global market owing to factors such as government’s initiative regarding growing awareness of advanced technologies . This is due to the widespread use of advanced treatment methods and the high prevalence of brain cancer.
The United States is the most promising market for brain cancer treatment due to favorable reimbursement landscape, aggressive awareness programmes, improved diagnostic measures, and the presence of major advanced therapy brands. The North American brain cancer market is forecasted to have a significant share over the forecast period. The United States market is supposed to take the lead, and this is due to the rise in the number of brain cancer patients, the developed healthcare industry, coupled with rising awareness regarding advanced technologies among the population in this region.
In the US more than 24530 adults (10690 women and 13840 men) will be diagnosed with primary cancerous tumors of the brain and spinal cord.
Meningioma is the most common type of brain cancer followed by gliomas, Eflornithin is designated as an orphan drug in the United States and received the breakthrough therapy designation for the treatment of anaplastic glioma. This is likely to positively impact the growth of the market over the forecast period.
Brain Cancer Treatment Market Competitive Landscape
The brain cancer treatment market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Novartis AG, Pfizer Inc, F.Hoffmann La Roche Ltd, Y-mAbS Therapeutics, Inc ,Merck & Co.Inc, Johnson & Johnson ,AstraZeneca, Bristol – Myers Squibb , Amgen Inc, GlaxoSmith Kline PLC.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the papillary thyroid carcinoma treatment market globally. For instance, in April 2021, D&D PharmaJet, Inc. (D&D), a clinical-stage biotechnology company, has entered into a sponsored research agreement with Yale University to optimize two novel approaches for the treatment of brain cancer and other disorders that allow immune system cells and drug molecules to bypass the blood-brain barrier (BBB). The BBB is a network of blood vessels and tissue made up of closely spaced cells that prevents harmful substances and many therapeutics from entering the brain.
Novartis AG
Overview: Novartis India Ltd. is an Indian based pharmaceutical company. The company is engaged in the trading of drugs and pharmaceuticals. It derives revenue from operations in India. The company focuses on three divisions namely Pharmaceuticals, eyecare and generic medicines.
Product Portfolio:
Capmatinib: Capmatinib is a drug that is used to treat brain cancer that has spread throughout the body. Capmatinib belongs to the kinase inhibitor class of drugs. It works by preventing cancer cells from multiplying by stopping the action of an aberrant protein. This slows or stops cancer cells from spreading.
